1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: (919) 286-6818
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma
A study of 94 Japanese men
Article first published online: 15 MAR 2002
DOI: 10.1002/cncr.10443
Copyright © 2002 American Cancer Society
Additional Information
How to Cite
Vollmer, R. T., Egawa, S., Kuwao, S. and Baba, S. (2002), The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma. Cancer, 94: 1692–1698. doi: 10.1002/cncr.10443
- †
Fax: (919) 286-6818
Publication History
- Issue published online: 15 MAR 2002
- Article first published online: 15 MAR 2002
- Manuscript Accepted: 26 NOV 2001
- Manuscript Revised: 30 OCT 2001
- Manuscript Received: 5 JUN 2001
REFERENCES
- 1. Serum prostate-specific antigen: the most useful tumor marker. J Clin Oncol. 1992; 10: 1205–1207.
- 2, , , et al. Results of radical prostatectomy in men with clinically localized prostate cancer. Multi-institutional pooled analysis. JAMA. 1996; 276: 615–619.
- 3, , , et al. Radiation therapy for clinically localized prostate cancer. A multi-institutional pooled analysis. JAMA. 1999;281: 1598–1604.
- 4, , , et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the prostate cancer center outcomes study. J Natl Cancer Inst. 2000; 92: 1582–1592.
- 5, . The natural history of clinical prostate carcinoma. Cancer. 1997; 80: 827–833.
- 6, , , et al. Results of conservative management of clinically localized prostate cancer. N Eng J Med. 1994; 330: 242–248.
- 7, , . Deferred treatment of clinically localized low-grade prostate cancer: actual 10-year and projected 15-year follow-up of the Karolinska series. Urology. 1997; 50: 722–726.
- 8, , , , . Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA. 1997;277: 467–471.
- 9, , , , . Long-term survival among men with conservatively treated localized prostate cancer. JAMA. 1995; 274: 626–631.
- 10Outcome research after radical retropubic prostatectomy for prostate cancer. J Natl Cancer Inst. 1998; 90: 1107.
- 11, , , . Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. J Urol. 1994; 152: 1905–1909.
- 12, . The prostate cancer intervention versus observation trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. J Urol. 1994; 152: 1910–1914.
- 13, , . Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer. 1993;71: 2031–2040.
- 14, , , . Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate cancer. Cancer. 1998;82: 342–348.
- 15, , . Serial prostate specific antigen measurements and progression in untreated confined (stages T0 to 3NxM0, grades 1 to 3) carcinoma of the prostate. J Urol. 1995; 154: 1403–1406.
- 16, , , , . Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy. J Urol. 1998; 159: 1243–1246.
- 17, . The dynamics of prostate-specific antigen after definitive radiation therapy for prostate cancer. Clin Cancer Res. 1999; 5: 4119–4125.
- 18, , . The dynamics of prostate-specific antigen in hormone refractory prostate cancer. An analysis of Cancer and Leukemia Group B study 9181 of megestrol acetate. Cancer. 1998;83: 1989–1994.
- 19, , , . A prognostic score for hormone refractory prostate cancer: analysis of two Cancer and Leukemia Group B studies. Clin Cancer Res. 1999; 5: 831–837.
- 20. Histologic grading of prostate cancer: a perspective. Hum Pathol. 1992; 23: 272–279.
- 21Urological tumors—prostate. In: SobinLH, WittekindCH, editors. International Union Against Cancer. TNM classification of malignant tumors. 5th ed. New York: John Wiley and Sons, Inc.; 1997: 170–173.
- 22, , , , , . Observations of prostate specific antigen doubling time in Japanese patients with nonmetastatic prostate carcinoma. Cancer. 1999; 86: 463–469.
- 23, , , et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res. 1992; 52: 3323–3328.
- 24, . Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer. 1993; 72: 2638–2643.
- 25, . Generalized linear models. 2nd ed. London: Chapman and Hall; 1989.
- 26, . Analysis of survival data. London: Chapman and Hall; 1984.